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Venous thromboembolic disease (VTE), comprising deep-vein 
thrombosis (DVT) and pulmonary embolism, is a leading cause of 
morbidity and mortality worldwide.[1-2] The prevalence of VTE in the 
South African (SA) population is currently poorly characterised and 
largely unknown.
In SA, there is a high dual burden of HIV and tuberculosis 
(TB), both of which have well-established associations with the 
development of VTE. There are several plausible explanations for the 
prothrombotic effect of these infections. These include induction of 
tumour necrosis factor alpha and interleukin-6 production by chronic 
infections, which renders the vascular endothelium thrombogenic, 
interference with the normal production of coagulation factors in 
the liver, an increase in the levels of factor VIII, fibrinogen and 
plasminogen activator inhibitor-1, and a reduction in antithrombin 
and protein C.[3-5] The causal relationship between TB and VTE is 
demonstrated in part by an improvement in the hypercoagulable state 
within 1 month of initiating anti-TB therapy.[4]
Recently implemented national diagnostic and treatment 
programmes in SA are rapidly changing the landscape of both HIV 
and TB.[6-7] Changes include an improvement in TB cure rates to 
~80%, a ~20% reduction in the number of new HIV cases, and an 
increase in antiretroviral therapy (ART) coverage.[6]
It is intended to introduce direct oral anticoagulants (DOACs) for 
the treatment of DVT in quaternary healthcare institutions. Their 
advantages include more predictable pharmacokinetics, allowing for 
standardised dosing and less frequent follow-up, which may improve 
long-term anticoagulation and compliance rates.[8] The current 
treatment of VTE with warfarin anticoagulation is challenging in 
the setting of comorbid HIV and/or TB because of the many drug 
interactions, particularly in patients on treatment for TB, in whom 
therapeutic international normalised ratio (INR) values can be 
difficult to achieve.[9] With the introduction of new DOACs it will be 
important to obtain baseline data on VTE prevalence, diagnosis and 
treatment in order to evaluate the benefit of these anticoagulants in 
an era of high HIV and TB prevalence and incidence.
Objectives
To characterise the clinical presentation, diagnosis, treatment and 
follow-up of VTE, with specific consideration of its association with 
HIV and TB infections, in a quaternary public sector healthcare 
setting in SA.
Methods
Study design and study population
This was a single-centre, prospective cohort study performed at 
Charlotte Maxeke Johannesburg Academic Hospital (CMJAH), a 
quaternary healthcare facility. The study, conducted from November 
2015 to January 2017, was reviewed and approved by the University 
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of the Witwatersrand Human Research Ethics Committee (ref. no. 
M150938) as well as the CMJAH management.
Study participants were unselected patients presenting to the 
Haematology Unit at CMJAH. Key inclusion criteria included signed 
informed consent by adults (≥18 years) with a new episode of DVT. 
These patients came to the Haematology Unit via the CMJAH 
Emergency Unit or through referrals from other centres, or were 
inpatients for whom the Haematology Unit was consulted to manage 
the DVT.
Physical examination and thrombosis pretest probability 
assessments (Wells score) were performed, and thrombosis was 
confirmed using a duplex Doppler examination (DDE). HIV 
status was established according to institutional procedure. Where 
indicated, thrombophilia screening was performed as part of the 
routine diagnostic work-up. Data collected included past medical 
history, concurrent diseases and treatment history, and blood samples 
were taken for routine haematology, coagulation and chemistry tests 
as per standard of care. These data were captured on a data collection 
sheet and anonymised prior to analysis.
Statistical analysis
Statistical analysis was performed using Stata 14 (StataCorp, 
USA) with the help of a statistician. Quantitative data were 
summarised in tables and figures and described using medians 
with interquartile ranges (IQRs), counts with percentages, Fisher’s 
exact test and the Mann-Whitney U-test. Statistical significance 
was set at p<0.05.
Results
Demographics and clinical presentation
During the 15-month study period, 126 individuals were referred 
to the Haematology Unit at CMJAH with clinical symptoms of 
DVT. Thrombosis was confirmed in 99 of these, and their pertinent 
demographic data are summarised in Table 1.
The clinical presentation was both pain and swelling of the limb 
in 60 participants (60.1%), with the remainder reporting either 
limb pain (n=5) or swelling (n=34). None of the participants were 
admitted specifically for symptoms of HIV or TB.
Diagnostic work-up
The thrombosis risk profile of the study population, stratified by HIV 
and TB status, is shown in Table 2.
The median Wells score was 3 (IQR 2 - 4). In the majority of cases 
the thrombosis occurred in the lower limb (n=97), with only two 
participants having upper limb thromboses.
The median D-dimer value in 93 participants tested was 1.71 (1 - 
3.67) mg/L. Four participants had a negative D-dimer result despite 
demonstrable thrombosis on DDE. The median waiting period for 
a DDE in 88 evaluable participants was 30 (24 - 36) hours, and 20 
participants waited >48 hours. DDE of 11 participants was done by 
the referring hospital or at CMJAH during admission, for another 
reason, prior to admission to the Haematology Unit.
Assays to investigate the cause of the thrombosis were performed 
in 64 participants on admission. All 64 had clotting assays done, 
while only 40 had molecular tests performed. The thrombophilia 
screening results are summarised in Table 3. The 64 clotting assays 
performed revealed a total of six abnormal results. There were no 
abnormal molecular results.
Management of thrombosis
Table 4 shows the follow-up and outcomes of the study participants. 
Of the 99 participants, 91 were initiated on a low-molecular-weight 
anticoagulant, enoxaparin sodium, and then given both enoxaparin 
sodium and a vitamin K antagonist, warfarin, once the diagnosis of 
thrombosis was made. The starting dose of warfarin was 5 mg with 
no loading dose. Enoxaparin sodium was given subcutaneously at 
1 mg/kg twice daily after admission. Once thrombosis was confirmed, 
enoxaparin sodium was continued for at least 5 days following the 
initiation of concomitant warfarin anticoagulation. Five participants 
were on enoxaparin sodium alone without warfarin – these were 
patients with malignancy (n=3) and those who were pregnant (n=2). 
Warfarin was stopped as soon as the INR was in the therapeutic 
range 2 - 3. Enoxaparin sodium was discontinued after a minimum 
of 5 days and once a therapeutic INR had been achieved. The median 
warfarin dose per week required to obtain a therapeutic INR was 30 
(IQR 20 - 43) mg and the median time to a therapeutic INR was 5.5 
(IQR 4.0 - 7.0) days. Of the 14 participants with cancer-associated 
thrombosis, only three (21.4%) were treated with enoxaparin sodium, 
which is the preferred treatment modality.[10-13] The median duration 
of hospitalisation in the cohort was 9 (IQR 7 - 11) days.
All participants were referred to the CMJAH INR clinic upon 
discharge for long-term follow-up. Of the 91 participants on warfarin, 
79 returned for follow-up at 1 month. During this period, adequate 
duration and consistency of anticoagulation therapy was achieved 
by 57 participants (72.2%). Eleven participants were lost to follow-
up. Twelve of the 99 participants (12.1%) died during the study 
period.
Comorbid HIV and TB infections
HIV status was established in 83 of the 99 participants. Forty-
four (53.0%) were HIV-positive, with a median CD4 count of 152 
(IQR 85 - 493) cells/µL and a median viral load of 482 (IQR 23 - 
221 250) copies/mL. Thirty-four of the 44 HIV-positive participants 
(77.3%) were on ART, three starting treatment while in hospital after 
the diagnosis of their DVT. Of the 10 participants who were not 
Table 1. Demographic data and baseline characteristics of 
participants (N=99)









Thrombosis investigation, n (%)
Duplex doppler confirmation 99 (100)
CTPA 5 (5.1)
Ventilation/perfusion scan 1 (1.0)
HIV† diagnosis and treatment, n (%)
Positive 44/83 (53.0)
Negative 39/83 (47.0)
On treatment 34/44 (77.3)
Not on treatment‡ 10/44 (22.7)
TB§ diagnosis and treatment, n (%) 21 (21.2)
On active treatment 17/21 (81.0)
Not on treatment 4/21 (19.0)
CTPA = computed tomography pulmonary angiogram; TB = tuberculosis.
*Determined by self-identification.
†Through objective laboratory testing.
‡ART was initiated during the hospitalisation of three patients.
§Pulmonary and extrapulmonary TB. 
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initiated on ART in hospital, two were not eligible, as they had just 
started TB treatment.
Of the 99 participants, 21 (21.2%) had a diagnosis of TB infection; 
in four cases this was diagnosed during hospitalisation. Seventeen 
participants were receiving TB treatment at the time of DVT 
diagnosis. HIV and TB co-infection was present in 20 participants. 
This group had a lower median CD4 count (118 (IQR 60 - 191) cells/
µL) than their HIV-positive, TB-negative counterparts (321 (IQR 
92 - 545) cells/µL) (p<0.05).
Discussion
This prospective cohort study provided baseline data on the clinical 
presentation, diagnostic work-up and management of 99 patients 
with DVT with or without HIV and/or TB infections in a quaternary 
public healthcare facility.
The median age of the patient cohort was 46 years, which reflects 
the age distribution in the adult haematology practice where the 
study was performed. This age is higher than the age of peak HIV 
prevalence at CMJAH, which is in the second and third decades. 
The racial distribution of the cohort mirrors that of the users of 
public healthcare facilities in SA. These figures would be different 
in the private healthcare sector and therefore do not reflect the true 
prevalence of thrombosis in the SA general population.
The clinical presentation of thrombosis in our patient cohort 
is similar to that elsewhere in the world.[14] Fifty-three percent of 
participants with thrombosis were also HIV-positive. This figure is 
similar to HIV-positivity rates in many public healthcare facilities 
in SA.[15-16]
TB was the most common risk factor for thrombosis in participants 
who were also HIV-positive. The burden of HIV and TB has begun 
to change in SA with the implementation of national diagnostic and 
treatment programmes. It remains to be seen whether this will in turn 
have an impact on the prevalence of thrombosis.
The work-up of participants with suspected DVT included the 
use of a clinical scoring system (the Wells score), and a quantitative 
D-dimer test, with confirmation on DDE. Studies have shown that 
DVT can safely be excluded in patients with the combination of a low 
Wells score and a negative quantitative D-dimer.[17-19] In our cohort, 
all four participants with a negative D-dimer had an intermediate 
Wells score and therefore went on to have a DDE to confirm 
thrombosis. The value of routinely using such an approach would be 
to limit the number of unnecessary DDEs.
Thrombophilia screening was performed in 64 participants, and 
six results were abnormal. This result is low relative to published 
studies, but the numbers are too small to establish an explanation. [20] 
Molecular tests for factor V Leiden and prothrombin G20210A 
mutations were negative in all 35 black participants in our study, a 
finding in keeping with previous studies confirming the absence of 
the factor V Leiden mutation in this population.[21-23]
Warfarin and enoxaparin sodium are currently the most widely 
used anticoagulants for the treatment of DVT in SA public hospitals. 
Their use at CMJAH was comparable to published national and 
international guidelines.[24-28] Enoxaparin sodium discontinuation 
Table 2. Risk factors for DVT by HIV and TB infection (N=99)
HIV+  
(N=24), n






Major general surgery 0 0 3 2
Orthopaedic surgery 0 0 0 1
Hospitalised for ≥3 days 1 0 1 0
Malignancy 5 0 7 2
Paralysis/stroke 2 0 1 2
TB treatment 0 16 1 0
Lower-limb cast 0 0 0 2
Oral contraceptive 0 2 5 0
Pregnancy 1 0 1 0
Postpartum 0 0 2 0
Central line 0 1 2 0
Long journey of 4 - 6 hours 0 0 1 3
DVT = deep-vein thrombosis; TB = tuberculosis; + = positive; – = negative.
*Either these participants refused testing, or there was no indication to do the HIV test.
Table 3. Assays for investigation of thrombosis aetiology
Thrombosis assay








Factor V Leiden 0
Prothrombin gene (G2021A) 0
APCR = activated protein C resistance.
Table 4. Patient follow-up during the study
Phases of follow-up Patients, n
Screening phase




Treated with VKA + LMWH 91





Lost to follow-up 11
Deaths* 9
VKA = vitamin K antagonist; LMWH = low-molecular-weight heparin.
*Probable causes of death were malignancy (n=8), sepsis (n=3) and stroke (n=1).
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procedures were adhered to in only 38% of participants. This low 
adherence is explained by both hospital- and patient-related factors, 
which included chronic bed shortages at CMJAH and inability 
of participants to be absent from work for extended periods. A 
more achievable target was therefore to obtain a minimum of one 
therapeutic INR and to administer at least 5 days of enoxaparin 
sodium before discontinuation. The use of enoxaparin sodium in 
cancer-associated thrombosis was low (21%) in our cohort. Plausible 
explanations include cost, lack of awareness of the current guidelines, 
clinician habit, safety concerns and the burden of daily injections for 
cancer patients.[29]
In the current study, the average duration of hospitalisation 
required to achieve a therapeutic INR was 1 - 2 weeks. Adequate 
and consistent long-term anticoagulation therapy was achieved in 
57 (72.2%) of the cohort, as shown in Table 4. Possible reasons for 
inadequate and inconsistent anticoagulation in the remaining 30% 
may include participants being unable to take time off work for 
follow-up visits and unaffordable transport costs.[30]
The introduction of DOAC therapy has the potential to reduce 
or eliminate the need for hospitalisation and testing, thus providing 
substantial cost savings for both hospitals and patients. However, 
studies predict that there will be significant drug interactions 
between DOACs and certain HIV and TB medications. There are 
known interactions with strong CYP3A4 inducers and inhibitors, 
namely rifampicin (standard of care) and protease inhibitors.[31-33] 
Based on these predictions, anticoagulation of patients with TB is 
likely to remain a challenge, as is currently experienced with warfarin 
anticoagulation. It is therefore anticipated that the benefits of DOACs 
may not be fully realised in patients with TB, and they are yet to be 
determined in those with HIV.
The HIV prevalence rate of 53.0% in our cohort was notably 
higher than the sub-Saharan African prevalence of 19.2%.[34] This 
finding probably reflects the prothrombotic risk associated with 
HIV. In addition to the direct effect of HIV on DVT development, 
opportunistic infections and their treatments, with associated 
prolonged bed rest and malignancies, are possible contributing 
factors in this subgroup. A significant proportion of the participants 
were on ART at the time of DVT diagnosis (77.3%), which indicates 
the efficiency of the national antiretroviral roll-out programme 
in SA. ART has been shown to reduce markers of coagulation, 
but abnormalities persist despite viral suppression. Twenty-one 
participants had comorbid HIV and TB, which reflects the scenario 
in the general population in this region. As expected, CD4 counts in 
this group were significantly lower than those in their TB-negative 
counterparts. Satisfactory anticoagulation therapy is a huge challenge 
in patients with TB infection owing to the unpredictable effects of 
rifampicin and isoniazid on the cytochrome P450 system, which is 
involved in warfarin metabolism.
Twelve participants (12.1%) died at various time points during the 
study, as shown in Table 4. The majority of the deaths occurred dur-
ing post-hospitalisation follow-up. The probable causes of death in 
these participants were malignancies (n=8), sepsis (n=3) and recent 
stroke (n=1). The malignancies were signet ring cell adenocarci-
noma, mesothelioma, breast, cervical, prostatic and bronchoalveolar 
carcinoma, and an unknown primary tumour. While no deaths due 
to thrombosis or bleeding complications were documented in the 
study, these remain possibilities for the 11 participants who were lost 
to follow-up.
Study limitations
The small patient population of 99 is an obvious limitation of this 
study. Our study figures therefore cannot be extrapolated to the 
general hospital population and may not reflect thrombosis as a 
whole in a quaternary care setting. The majority of the participants 
in this study had lower-limb thromboses. We would not have seen 
patients with other sites of thrombosis, such as intra-abdominal and 
pulmonary, if they were managed by other disciplines of medicine. 
Finally, the follow-up of 3 months was short and may not reflect the 
true outcome of management of thrombosis in a quaternary care 
setting in the long term.
Conclusion
This prospective study provides real-life data on the prevalence 
of DVT in the pre-DOAC era. The data will serve as a baseline 
reference for measuring the effectiveness and impact of the 
new DOACs when used routinely outside clinical trials. This is 
of particular interest in patients with comorbid HIV and TB, 
where conventional anticoagulation treatment is challenging. 
The prevalences of HIV and TB observed in this study provide 
an important reference point for assessing the aetiological 
association between thrombosis and these infections, especially 
as their prevalence changes as a result of the current national 
interventions. To elucidate the aetiological association of HIV 
and TB with thrombosis fully, further research into the underlying 
pathophysiological mechanisms is required.
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